New scan could spot breast cancer protein without needle
NCT ID NCT03991260
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested a new radioactive imaging agent called 99mTc-ADAPT6 to see if it can detect HER2 protein in breast cancer tumors using SPECT scans. Sixteen women with primary breast cancer received a single injection, followed by scans over six hours. The goal was to compare the imaging results with standard biopsy tests to see if the agent can accurately identify HER2 status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled ADAPT6
What this could lead to
If successful, this could provide a non-invasive way to determine HER2 status in breast cancer, potentially guiding treatment without needing a biopsy.
What could go wrong
This was a very small, early-phase study with only 16 participants, so results may not apply to all patients. The imaging agent may not accurately distinguish HER2-positive from HER2-negative tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia